Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.74 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.66 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.59 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075944 | 1.00 | ADK (0.74) | ADKMETTL3METTL14SLC29A1PRMT5 | |
| SCHEMBL31237241 | 1.00 | ADK (0.74) | ADKMETTL3METTL14SLC29A1PRMT5 | |
| SCHEMBL23982517 | 0.89 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL30047254 | 0.89 | ADK (0.73) | ADKMETTL3METTL14SLC29A1PRMT5 | |
| SCHEMBL30689918 | 0.89 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL20419319 | 0.89 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL17816362 | 0.89 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL20419313 | 0.89 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL15477884 | 0.85 | METTL3 (0.79) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL15570446 | 0.85 | METTL3 (0.79) | ADKMETTL3METTL14SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | claimed |
| EP-4142744-A1 | MESENCHYMAL STEM CELL THERAPIES | Factor Bioscience Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| EP-1572097-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-09-14 | — | — | EP | claimed |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-07-29 | — | — | US | claimed |
| WO-2004028481-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| EP-4329783-A1 | COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES FOR FANCONI ANEMIA | STRM.Bio Incorporated (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4301848-A1 | ENGINEERED IMMUNE CELL THERAPIES | Factor Bioscience Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023205424-A2 | LIPID COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY | GREENLIGHT BIOSCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4232005-A1 | COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES FOR TREATING MYELOPROLIFERATIVE NEOPLASMS | STRM.Bio Incorporated (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | disclosed |
| EP-4150054-A1 | COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES | Sterm.Bio Incorporated (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4142744-A1 | MESENCHYMAL STEM CELL THERAPIES | Factor Bioscience Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022187704-A1 | ENGINEERED IMMUNE CELL THERAPIES | FACTOR BIOSCIENCE INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022087505-A1 | COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES FOR TREATING MYELOPROLIFERATIVE NEOPLASMS | STRM.BIO INCORPORATED (US) | 2022-04-28 | — | — | WO | disclosed |
| US-7629320-B2 | Nucleoside derivatives for treating hepatitis C virus infection | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080249060-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-7425547-B2 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1572097-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004028481-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249060-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | HAVCR2, PNP, NTPCR | ADK 222/4885METTL3 587/4885METTL14 1882/4885 |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADK 222/4885METTL3 587/4885METTL14 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.